Building Biotechnology - Starting, managing, and understanding biotechnology companies. Your guide to the business of biotechnology. (Biotechnology book)


	Case Studies Cytochrome p450 and pharmacogenomics Pharmacogenomics: Defining, and excluding, patients cGMP: Building quality into products Blue jeans and biotechnology ESTs lack utility and enablement without proven use When research is done abroad Amgen v. Transkaryotic Therapies: Strategic patenting Monsanto gets hit by $185 million torpedo The SNP Consortium Erbitux: Poor study design Vioxx: Anticipating and disclosing side-effects Fen-Phen: Off-label use AIDS and accelerated approval The disproportionate returns of orphan drug research Starlink corn: Controlling biotechnology crops Directing science: The war on cancer State autonomy and federal laws Presidential politics and biotechnology Non-profit drug development Flavr Savr tomatoes Entrepreneurial leadership in an established biotechnology company Venture capital: The poker analogy Alternative route to going public Clinical trials provide valuation milestones Valuation of biotechnology companies Cetus flies too high Dangers of not having a pipeline Focus on free cash flow Research Triangle Park Developing biotechnology without venture capital in your backyard Chiron's flu vaccine facility loses license Licensing technology or keeping it in-house Enbrel: Coping with success The use of biotechnology in U.S. industries

Building Biotechnology is a product of thinkBiotech